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Prevention of multiple pregnancies in couples with
unexplained or mild male subfertility: randomised
controlled trial of in vitro fertilisation with single
embryo transfer or in vitro fertilisation in modified
natural cycle compared with intrauterine insemination
with controlled ovarian hyperstimulation
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Abstract
Objectives To compare the effectiveness of in vitro fertilisation with
single embryo transfer or in vitro fertilisation in a modified natural cycle
with that of intrauterine insemination with controlled ovarian
hyperstimulation in terms of a healthy child.
Design Multicentre, open label, three arm, parallel group, randomised
controlled non-inferiority trial.
Setting 17 centres in the Netherlands.
ParticipantsCouples seeking fertility treatment after at least 12 months
of unprotected intercourse, with the female partner aged between 18
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and 38 years, an unfavourable prognosis for natural conception, and a
diagnosis of unexplained or mild male subfertility.
Interventions Three cycles of in vitro fertilisation with single embryo
transfer (plus subsequent cryocycles), six cycles of in vitro fertilisation
in a modified natural cycle, or six cycles of intrauterine insemination with
ovarian hyperstimulation within 12 months after randomisation.
Main outcome measures The primary outcome was birth of a healthy
child resulting from a singleton pregnancy conceived within 12 months
after randomisation. Secondary outcomes were live birth, clinical
pregnancy, ongoing pregnancy, multiple pregnancy, time to pregnancy,
complications of pregnancy, and neonatal morbidity and mortality
Results 602 couples were randomly assigned between January 2009
and February 2012; 201 were allocated to in vitro fertilisation with single
embryo transfer, 194 to in vitro fertilisation in a modified natural cycle,
and 207 to intrauterine insemination with controlled ovarian
hyperstimulation. Birth of a healthy child occurred in 104 (52%) couples
in the in vitro fertilisation with single embryo transfer group, 83 (43%) in
the in vitro fertilisation in a modified natural cycle group, and 97 (47%)
in the intrauterine insemination with controlled ovarian hyperstimulation
group. This corresponds to a risk, relative to intrauterine insemination
with ovarian hyperstimulation, of 1.10 (95% confidence interval 0.91 to
1.34) for in vitro fertilisation with single embryo transfer and 0.91 (0.73
to 1.14) for in vitro fertilisation in a modified natural cycle. These 95%
confidence intervals do not extend below the predefined threshold of
0.69 for inferiority. Multiple pregnancy rates per ongoing pregnancy were
6% (7/121) after in vitro fertilisation with single embryo transfer, 5%
(5/102) after in vitro fertilisation in a modified natural cycle, and 7%
(8/119) after intrauterine insemination with ovarian hyperstimulation (one
sided P=0.52 for in vitro fertilisation with single embryo transfer compared
with intrauterine insemination with ovarian hyperstimulation; one sided
P=0.33 for in vitro fertilisation in a modified natural cycle compared with
intrauterine insemination with controlled ovarian hyperstimulation).
Conclusions In vitro fertilisation with single embryo transfer and in vitro
fertilisation in a modified natural cycle were non-inferior to intrauterine
insemination with controlled ovarian hyperstimulation in terms of the
birth of a healthy child and showed comparable, low multiple pregnancy
rates.
Trial registration Current Controlled Trials ISRCTN52843371;
Nederlands Trial Register NTR939.
Introduction
Involuntary childlessness affects more than 70 million couples
worldwide and has a large impact on quality of life, leading to
lasting psychosocial effects.1 2 Most couples will seek fertility
care and consult their general practitioner for guidance.
Approximately half of these couples will be diagnosed as having
unexplained or mild male subfertility.3 Most of them still have
a good chance of conceiving andwill achieve pregnancywithout
treatment.4 5 Treatment is thus indicated only if the chances of
conceiving naturally are low and the success rate after treatment
exceeds this probability.6 7
Intrauterine insemination with controlled ovarian
hyperstimulation is the first line fertility treatment in couples
with an unfavourable prognosis for natural conception.8 9
However, concern exists about the increased rates of multiple
pregnancy after intrauterine inseminationwith controlled ovarian
hyperstimulation, as a result of the stimulation of multiple
follicles.10 Intrauterine insemination with controlled ovarian
hyperstimulation results in pregnancy rates of 13% per cycle at
the expense of a multiple pregnancy rate that is estimated to be
above 10% per ongoing pregnancy.6 11Multiple pregnancies are
associated with maternal morbidity such as pre-eclampsia,
gestational diabetes, and a 50% risk of premature delivery,
resulting in considerable neonatal morbidity and mortality.12
In vitro fertilisation with single embryo transfer is increasingly
implemented and might be equally effective but safer, as it
prevents multiple pregnancies.13-15 Live birth rates with the
transfer of one good quality embryo are 28% per cycle, with
multiple pregnancy rates as low as 1% per live birth.16 The
downside of in vitro fertilisation is that it is an invasive and
burdensome procedure with higher costs.17
In vitro fertilisation in a modified natural cycle—a cycle in
which monofollicular growth results in one oocyte at follicular
aspiration and in one embryo after fertilisation—might be
another treatment option. In vitro fertilisation with unstimulated
or mildly stimulated regimens are becoming more popular.18-21
Cumulative live birth rates over six cycles of more than 30%
have been reported, with almost no multiple pregnancies.22 In
vitro fertilisation in a modified natural cycle has been advocated
as less burdensome and less costly than “conventional” in vitro
fertilisation.22 23
Multiple pregnancies seem to be prevented by in vitro
fertilisation with single embryo transfer and in vitro fertilisation
in a modified natural cycle, but this will be acceptable only if
these interventions are as effective as intrauterine insemination
with controlled ovarian hyperstimulation in terms of live birth
rates. We therefore designed a randomised trial to evaluate the
effectiveness of these interventions in terms of healthy children
born from singleton pregnancies.
Methods
We did a multicentre, open label, three arm, parallel group,
randomised controlled non-inferiority trial in 17 fertility clinics
in the Netherlands between January 2009 and February 2013.
Full details of the trial protocol can be found at www.studies-
obsgyn.nl/ines.
Participants
Couples seeking fertility treatment after at least 12 months of
unprotected intercourse were eligible. All participating couples
provided written informed consent. All couples underwent basic
fertility investigations, which included semen analysis,
evaluation of ovulation, and tubal patency testing (Chlamydia
antibody test, hysterosalpingography or laparoscopy). Inclusion
criteria were age of female partner between 18 and 38 years, an
unfavourable prognosis for natural conception, and a diagnosis
of unexplained or mild male subfertility. We classified couples
as having unexplained subfertility when the fertility
investigations showed at least one patent fallopian tube, an
ovulatory menstrual cycle, and a normal semen analysis
(pre-wash total motile sperm count above 10 million).24 We
considered couples who qualified for intrauterine insemination
with donor sperm after at least six cycles of artificial
intracervical inseminationwith donor sperm to have unexplained
subfertility for the purpose of this study. Mild male subfertility
was diagnosed when the semen analysis showed a pre-wash
total motile sperm count between three and 10 million
(according to the Dutch guidelines).We defined an unfavourable
prognosis for natural conception as a probability of natural
conception within the next 12 months of less than 30%, as
calculated with the validated synthesis model of Hunault.7 This
model encompasses female age, duration of subfertility, whether
subfertility is primary or secondary, percentage of motile
progressive sperm, and referral status. It is readily available for
all clinicians (www.freya.nl/web_bereken/bereken.php).
Exclusion criteria were anovulation, double sided tubal disease,
severe endometriosis, premature ovarian failure, and known
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endocrine disorders (such as Cushing’s syndrome or adrenal
hyperplasia).
Randomisation and masking
Couples were randomly allocated in a 1:1:1 ratio to receive
either three consecutive cycles of in vitro fertilisation with single
embryo transfer plus subsequent cryocycles, six consecutive
cycles of in vitro fertilisation in a modified natural cycle, or six
consecutive cycles of intrauterine insemination with controlled
ovarian hyperstimulation within 12months. Randomisation was
performed with an online randomisation program, using biased
coin minimisation, stratified for study centre. A web based
program generated a unique number with allocation code after
entry of the patient’s initials and date of birth. Neither the
recruiters nor the trial project group could access the
randomisation sequence. Blinding was not possible owing to
the nature of the interventions.
Interventions
In the in vitro fertilisation with single embryo transfer group,
participating hospitals could adhere to local stimulation
protocols, which were either long/short agonist or antagonist
protocols. Controlled ovarian hyperstimulation started with 150
IU follicle stimulating hormone. Treatment was continued until
at least two follicles of at least 18 mm had developed. Ovulation
triggering was induced by 10 000 IU human chorionic
gonadotropin hormone (Pregnyl, Merck Sharp & Dohme), and
cumulus-oocyte complexes were recovered by transvaginal
ultrasound guided retrieval 36 hours thereafter.
We adhered to an elective single embryo transfer policy: if one
good quality embryowas available, we transferred one embryo.25
If more than one good quality embryo was available, suitable
surplus embryos were cryopreserved. If no good quality embryos
were available, two embryos would be transferred. For the
morphological score, the degree of fragmentation of the embryo
and the uniformity of the blastomeres were assessed daily.26 The
embryo was given a score of 1 (no fragmentation), 2 (<20%
fragmentation), 3 (20-50% fragmentation), or 4 (>50%
fragmentation). We defined good quality embryos as those with
a cumulative embryo score of 24 or higher. Embryo transfer
followed on day three. All available frozen embryos were
transferred after thawing before a new treatment cycle was
started.
During our trial, the results of a pilot study, randomising women
to three cycles of intrauterine insemination with controlled
ovarian hyperstimulation or one cycle of in vitro fertilisation
with single embryo transfer, was published. This pilot study
showed that the policy of transferring two embryos when no
good quality embryos are available is not effective in preventing
multiple pregnancies.27 We amended our study protocol, and
from February 2010, after allocation of 48 women to the in vitro
fertilisation with single embryo transfer group, a strict single
embryo transfer policy was implemented (that is, single embryo
transfer was performed irrespective of the quality of the
embryo).
In the in vitro fertilisation in a modified natural cycle group,
women were monitored by transvaginal ultrasound from days
eight to 10 of the cycle onward; when the lead follicle had a
mean diameter of at least 14 mm, they were given daily
injections of 0.25 mg of the gonadotropin releasing hormone
antagonist to prevent premature ovulation together with 150 IU
follicle stimulating hormone to prevent collapse of the follicle
and a concomitant fall in oestradiol concentrations. Follicle
stimulating hormone was continued up to the day of the
ovulation triggering, and the gonadotropin releasing hormone
antagonist was last given on the day of ovulation triggering.
When a follicle with a diameter of 17-18 mm was observed,
ovulation triggering was achieved by subcutaneous injection of
10 000 IU of human chorionic gonadotropin. Oocyte retrieval
was planned 34 hours thereafter and was performed without
anaesthesia or sedation. If an oocyte was obtained and fertilised,
the embryo was transferred on day three. For luteal support,
human chorionic gonadotropin 1500 IU was given by
subcutaneous injections on days five, eight, and 11 after oocyte
retrieval. The next treatment cycle could start immediately after
the previous cycle.
In the intrauterine insemination with controlled ovarian
hyperstimulation group, women received controlled ovarian
hyperstimulation according to the local protocol, with either
100 mg clomiphene citrate (cycle day three to seven) or daily
subcutaneous injections of 75 IU follicle stimulating hormone
(starting dose). Follicular growth was monitored by ultrasound;
when at least one follicle of 17 or 18 mm was present, final
oocyte maturation was induced by the administration of 5000
IU human chorionic gonadotropin. Approximately 36 hours
thereafter, intrauterine insemination was performed. Intrauterine
insemination with controlled ovarian hyperstimulation cycles
were cancelled when there were more than three follicles with
a diameter of 16 mm or more than five follicles with a diameter
of 12 mm. Those couples were instructed to refrain from
unprotected intercourse. The box summarises the three
interventions.
Follow-up
Couples were followed up for 12 months after randomisation.
We included all interventions that couples received within 12
months after randomisation. A pregnancy test was performed
two weeks after embryo transfer or intrauterine insemination.
Clinical and ongoing pregnancies were confirmed by
ultrasonography. If a miscarriage occurred within 12 months
after randomisation, couples could continue their allocated
treatment. Natural conceptions were also included in the analysis
in the three groups.
Outcomes
The primary outcome was the birth of a healthy child, resulting
from a singleton pregnancy conceived within 12 months after
randomisation. A child was considered healthy when born at
term, defined as a gestational age between 37 and 42 weeks;
with a birth weight above the fifth centile according to the Dutch
reference curves corrected for parity, sex, and ethnicity; without
congenital anomalies; and developing normally up to six weeks
after birth.28 This information was collected from the parents,
child health centres, or paediatricians.
Secondary outcomes were any live birth, multiple pregnancy
(registered heartbeat of at least two fetuses at 12 weeks of
gestation), clinical pregnancy (any registered embryonic
heartbeat on ultrasound), ongoing pregnancy (registered
heartbeat of a fetus at 12 weeks of gestation), neonatal mortality
(death of the child within 28 days after birth), neonatal morbidity
(preterm birth <37 weeks, birth weight <2500 g), pregnancy
complications, (pregnancy induced hypertension,
(pre-)eclampsia, HELLP syndrome), and time to pregnancy.
All serious adverse events were reported to the trial coordinator.
An independent data safety and monitoring committee
(consisting of two gynaecologists and one statistician) monitored
the progress of the study and the safety of the women and did
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The three interventions
Intrauterine insemination with controlled ovarian hyperstimulation
• Hyperstimulation from cycle day 3 or 4; start with 100 mg clomiphene citrate or subcutaneous injections of 75 IU FSH
• Monitoring of follicular growth by transvaginal ultrasound
• Induction of final oocyte maturation with 5000 IU of hCG when ≥1 follicle with diameter of 17 or 18 mm
• IUI 36 hours thereafter
Cancel criteria: hCG administration and IUI will be withheld when >3 follicles with diameter of 16 mm or >5 follicles with diameter of 12 mm
In vitro fertilisation in modified natural cycle
• Ultrasound monitoring from cycle day 8-10 with monitoring of serum concentrations of LH and oestradiol
• Start daily injections of 0.25 mg of GnRH antagonist with 150 IU FSH when lead follicle with mean diameter of ≥14 mm
• Ovulation induction with 10 000 IU hCG when one follicle with diameter of 17-18 mm or LH >30 with follicle >15 mm
• Oocyte retrieval 34 hours thereafter
• Embryo transfer day 2 or 3 after oocyte retrieval
• Luteal support, hCG 1500 IU on days 5, 8, and 11
Cancel criteria: LH rise of >30 IU/L noticed at follicle size of <15 mm
In vitro fertilisation with single embryo transfer
• Down regulation with GnRH agonist in long/short protocol or fixed start antagonist protocol; stimulation start dose 150 IU FSH
• Ultrasound monitoring according to local protocol
• Ovulation induction with 10 000 IU hCG until ≥2 follicles >18 mm
• Oocyte retrieval 36 hours thereafter.
• Embryo transfer day 2, 3, or 4.
• Cryopreservation of non-transferred good quality embryos (one embryo will be transferred per freeze-thaw cycle if it is of good quality)
Cancel criteria: ovarian hyperstimulation syndrome, non-response
FSH=follicle stimulating hormone; GnRH=gonadotropin releasing hormone; hCG = human chorionic gonadotropin;
IUI=intrauterine insemination; LH=luteinising hormone
a blinded interim analysis to exclude large differences after 300
inclusions with ongoing pregnancy as a surrogate outcome.
Study design, sample size, and statistical
analysis
The trial was designed as a non-inferiority trial. The null
hypothesis assumed that the pregnancy rates would be
comparable between all interventions. We expected 40% of the
couples to have a live birth within 12 months after starting with
intrauterine insemination with controlled ovarian
hyperstimulation.29 For the power calculation, using a 5%
significance level, we needed 190 couples to achieve 80% power
to exclude a difference of 12.5% or more to the detriment of in
vitro fertilisation with single embryo transfer and in vitro
fertilisation in a modified natural cycle. This difference
corresponds to a relative risk of 0.69. To account for a 5% loss
to follow-up, we needed to include 200 couples in each group.
All randomised patients were included in all analyses. We
estimated differences in the primary and secondary outcomes
as relative risks with 95% confidence intervals. We constructed
Kaplan-Meier survival curves in each treatment group for the
time to ongoing pregnancy with a healthy child. We used SPSS
(version 20.0) for all statistical analyses.We considered P values
below 0.05 as indicating statistically significant differences.
Results
Between January 2009 and February 2012, 869 couples fulfilled
the inclusion criteria and were invited to the trial, of whom 267
declined randomisation. We included 602 couples: 201 couples
were assigned to in vitro fertilisation with single embryo
transfer, 194 to in vitro fertilisation in a modified natural cycle,
and 207 to intrauterine insemination with controlled ovarian
hyperstimulation (fig 1⇓). Baseline characteristics in the three
groups were comparable (table 1⇓).
Tables 2⇓ and 3⇓ list all interventions that took place during
the 12months’ follow-up. Table 2⇓ shows the number of couples
who received the allocated treatment per cycle, and table 3⇓
shows the total number of cycles within 12 months. Table 2⇓
also shows additional treatments that couples received when
they switched from the allocated treatment to another treatment
or when they continued with another treatment after having
completed their allocated treatment within 12 months after
randomisation.
In the in vitro fertilisation with single embryo transfer group,
15% (30/201) of the couples discontinued treatment before
receiving three fresh cycles of in vitro fertilisation with single
embryo transfer or achieving pregnancy. Discontinuation rates
were 23% (45/194) in the in vitro fertilisation in a modified
natural cycle group and 13% (26/207) in the intrauterine
insemination with controlled ovarian hyperstimulation group.
These couples discontinued treatment because they switched to
another treatment or chose to end treatment.
Pregnancy outcomes
Table 4⇓ lists the outcomes of pregnancy. In all, 104 (52%)
couples had healthy children after in vitro fertilisation with
single embryo transfer, 83 (43%) after in vitro fertilisation in a
modified natural cycle, and 97 (47%) after intrauterine
insemination with controlled ovarian hyperstimulation. This
corresponds to a relative risk, compared with intrauterine
insemination with controlled ovarian hyperstimulation, of 1.10
(95% confidence interval 0.91 to 1.34) for in vitro fertilisation
with single embryo transfer and 0.91 (0.73 to 1.14) for in vitro
fertilisation in a modified natural cycle. These 95% confidence
intervals do not extend below the predefined threshold of 0.69
for inferiority.
We found no evidence of a difference between the groups in
rates of live birth, ongoing pregnancy, or clinical pregnancy.
Multiple pregnancy rates were 6% after in vitro fertilisation
with single embryo transfer, 5% after in vitro fertilisation in a
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modified natural cycle, and 7% after intrauterine insemination
with controlled ovarian hyperstimulation (one sided P=0.52 for
in vitro fertilisation with single embryo transfer compared with
intrauterine insemination with controlled ovarian
hyperstimulation; one sided P=0.33 for in vitro fertilisation in
a modified natural cycle compared with intrauterine
insemination with controlled ovarian hyperstimulation). One
triplet pregnancy occurred in the intrauterine insemination with
controlled ovarian hyperstimulation group; all other multiple
pregnancies were twin pregnancies.
In the 48 couples who received in vitro fertilisation with single
embryo transfer before the amendment of the protocol, 22 (46%)
women had a healthy singleton child and three (6%) women
had healthy twins. In the 153 couples who received strict in
vitro fertilisation with single embryo transfer after the
amendment of the protocol, 82 (54%) women had a healthy
singleton and four (3%) women had twins.
Neonatal outcomes
Neonatal death did not occur in this study. We found no
differences between groups in the relative number of preterm
babies or in those with low birth weight (<2500 g) (table 4⇓).
Congenital anomalies were reported in 10 cases (table 4⇓).
According to the ICD-10 (international classification of diseases,
10th revision) classification, one case of an aortic stenosis (Q23)
occurred in the in vitro fertilisation with single embryo transfer
group. One case of an urachus fistula (Q64), one case of
Moebius syndrome (Q87), and two cases of Down’s syndrome
(Q90) occurred in the in vitro fertilisation in a modified natural
cycle group. In the intrauterine insemination with controlled
ovarian hyperstimulation group, one case of patent/persistent
foramen ovale (Q21), one case of congenital deafness (H90),
one case of an umbilical hernia (K42), one case of Down’s
syndrome (Q90), and one case of oesophageal atresia (Q39)
occurred.
Maternal outcomes
Two women in the in vitro fertilisation with single embryo
transfer group and one woman in the intrauterine insemination
with controlled ovarian hyperstimulation group developed
ovarian hyperstimulation syndrome, and all were managed
expectantly: two were managed in an outpatient setting, and
one was admitted for one night. Pregnancy induced
hypertension, pre-eclampsia, and HELLP syndrome occurred
at similar frequencies in the three groups (table 4⇓).
Time to pregnancy
Average time to pregnancy leading to a healthy child was 8.04
months for in vitro fertilisation with single embryo transfer,
8.32 months for in vitro fertilisation in a modified natural cycle,
and 8.39 months for intrauterine insemination with controlled
ovarian hyperstimulation (fig 2⇓). The differences were not
statistically significant for in vitro fertilisation with single
embryo transfer (log rank: P=0.38) or for in vitro fertilisation
in a modified natural cycle (log rank: P=0.59) compared with
intrauterine insemination with controlled ovarian
hyperstimulation.
Figure 3⇓ shows time to ongoing pregnancy within 12 months
after randomisation, classified as to whether the pregnancy was
achieved with the allocated treatment, with additional treatment,
or after natural conception. Twenty four (12%) couples had a
live birth after natural conception in the in vitro fertilisation
with single embryo transfer group, 30 (15%) in the in vitro
fertilisation in a modified natural cycle group, and 22 (11%) in
the intrauterine insemination with controlled ovarian
hyperstimulation group. Of the pregnancies achieved through
allocated treatment in the in vitro fertilisation with single embryo
transfer group, 68 (76%) were ongoing pregnancies after fresh
embryo transfer and 21 (24%) after frozen embryo transfer.
Discussion
In this multicentre, open label, three arm, parallel group,
randomised controlled non-inferiority trial, we showed that in
vitro fertilisation with single embryo transfer and in vitro
fertilisation in a modified natural cycle are non-inferior to
intrauterine insemination with controlled ovarian
hyperstimulation in terms of the birth of a healthy child in
couples with unexplained or mild male subfertility and
unfavourable fertility prospects. Rates of multiple pregnancy
in all three treatment arms were comparable and amounted to
less than 7%. Also, time to pregnancy was comparable in all
arms.
Strengths and weaknesses of study
Couples were treated with three cycles of in vitro fertilisation
with single embryo transfer, six cycles of in vitro fertilisation
in a modified natural cycle, or six cycles of intrauterine
insemination with controlled ovarian hyperstimulation during
12months to determine the chances of pregnancy over a realistic
time period following treatment, reflecting daily clinical
practice. Also, all additional interventions or pregnancies
achieved through natural conception within the 12 months after
randomisation were registered and included in the analysis.
The trial was further strengthened by our primary outcome, the
birth of a single healthy child. The European Society for Human
Reproduction and Embryology (ESHRE) has recommended
this outcome measure, as the primary aim of reproductive
medicine is to help couples with an unfulfilled wish for a child
to have a healthy child.30 Our criteria for a healthy child were
quite strict, but if these were softened to include healthy late
preterm infants, more children born out of a twin pregnancy in
our study would be considered healthy.
We initially chose elective single embryo transfer on the basis
of data from a meta-analysis that showed that elective single
embryo transfer in patients with a good prognosis resulted in a
higher chance of delivering a term singleton live birth, compared
with double embryo transfer. Birth rates overall were lower, but
this could almost be compensated by additional cycles of frozen
single embryo transfer.31 Our change in policy from elective
single embryo transfer to a policy of strict single embryo transfer
did not lead to lower pregnancy rates but did lead to lower
multiple pregnancy rates. The four dizygotic twin pregnancies
after the policy change occurred after double embryo transfer
at the request of the patients. This shows the difficulty in
maintaining a rigid policy of in vitro fertilisation with single
embryo transfer and in vitro fertilisation in a modified natural
cycle.
The margin of equivalence, 12.5%, may be seen as relatively
high, as one could argue that a 5% or 10% increase may be
important in clinical practice. We hypothesised that the
pregnancy rates of in vitro fertilisation had to be considerably
better than those of intrauterine insemination with controlled
ovarian hyperstimulation, as in vitro fertilisation is a more
invasive and expensive treatment, and we considered 12.5% to
be reasonable in this respect.
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Generalisability
We included only couples with chances of conceiving below
30%, as it has been established that intrauterine insemination
with controlled ovarian hyperstimulation is not effective in
couples with chances of natural conception greater than 30%
according to the Hunault model.6 The use of this prediction
model obviates the need to minimise by female age, parity, and
duration of subfertility, as all these factors are incorporated in
the model.
We included only couples with women aged under 38 years, as
this age limit had often been used in studies comparing single
embryo transfer with double embryo transfer in couples with
good prognosis.32-35As a consequence, we did not want to expose
couples in which the woman is at the end of her reproductive
period to single embryo transfer.
Interpretation in context of setting and
intervention
Results from this trial partly confirm the findings of a
meta-analysis.36 This Cochrane review included four trials, and
the results suggested that among treatment naïve couples with
unexplained subfertility, no significant difference existed in live
birth rates for intrauterine insemination with controlled ovarian
hyperstimulation versus in vitro fertilisation. However, two
recent trials concluded that pregnancy was achieved faster with
immediate in vitro fertilisation.37 38 Apart from differences in
population, the stimulation protocols were more aggressive than
ours, and the multiple pregnancy rates were higher. We found
no significant difference in time to pregnancy in the three arms
of our study, so no time is wasted by starting with intrauterine
insemination with controlled ovarian hyperstimulation.
Many couples stop treatment or switch to another treatment
before an ongoing pregnancy is achieved. By allowing couples
to receive other treatments if they did not achieve an ongoing
pregnancy leading to a live birth after in vitro fertilisation with
single embryo transfer, in vitro fertilisation in a modified natural
cycle, or intrauterine insemination with controlled ovarian
hyperstimulation within a time horizon of one year, our study
design reflects daily practice and leads to high external validity.
As we have excluded large differences in efficacy and safety
between in vitro fertilisation with single embryo transfer and
in vitro fertilisation in a modified natural cycle compared with
intrauterine insemination with controlled ovarian
hyperstimulation, costs and patients’ preferences should be
considered. The number of couples who discontinue treatment
if a pregnancy does not occur can be considered a proxy for the
burden of treatment. In this trial, in vitro fertilisation in a
modified natural cycle had a higher rate of couples discontinuing
treatment. From that perspective, in vitro fertilisation in a
modified natural cycle might not be as patient friendly as
previously considered.22
The number of multiple pregnancies in the intrauterine
insemination with controlled ovarian hyperstimulation group
was lower in this trial than previously reported.39-41 We aimed
to achieve a maximum of three dominant follicles and used
strict cancellation criteria. This resulted in low chances of
multiple pregnancy while maintaining live birth rates, indicating
the relative safety of intrauterine insemination with controlled
ovarian hyperstimulation when strict criteria are maintained.11
Our rather cautious approach to stimulation also resulted in
induction of ovulation and subsequent intrauterine insemination
when only one mature follicle was present. Furthermore,
intrauterine insemination with controlled ovarian
hyperstimulation was performed with either clomiphene citrate
or follicle stimulation hormone; this may have influenced the
rates of both pregnancy and multiple pregnancy. Whether the
use of clomiphene citrate should be preferred over follicle
stimulating hormone in intrauterine insemination with controlled
ovarian hyperstimulation cycles in couples with unexplained
subfertility is being studied in a randomised controlled (Dutch
trial registration (www.trialregister.nl) number 4057).
We found comparable rates of multiple pregnancy between the
three interventions. This would suggest that in vitro fertilisation
with single embryo transfer or in vitro fertilisation in a modified
natural cycle has no benefit in the reduction of multiple
pregnancies over intrauterine insemination with controlled
ovarian hyperstimulation. However, if a twin pregnancy must
be avoided at all costs, intrauterine insemination with controlled
ovarian hyperstimulation should not be performed, as a small
risk of a multiple pregnancy still exists. In vitro fertilisation
with the transfer of a single embryo, irrespective of embryo
quality, should be the treatment of choice, whether after in vitro
fertilisation in a modified natural cycle or in vitro fertilisation
in a modified natural cycle with conventional ovarian
hyperstimulation. To the detriment of in vitro fertilisation in a
modified natural cycle, no surplus embryos are available for
cryopreservation.
Recently, the question was posed as to whether couples with
unexplained subfertility and an unfavourable prognosis for
natural conception should be treated at all. The updated 2013
guideline from the National Institute for Health and Care
Excellence abandoned intrauterine insemination with controlled
ovarian hyperstimulation for these couples and recommended
extended expectant management for all couples with
unexplained subfertility instead, on the basis of a lack of data
indicating efficacy of intrauterine insemination for unexplained
subfertility.42 However, trials comparing intrauterine
insemination with controlled ovarian hyperstimulation versus
extended expectantmanagement in couples with an unfavourable
prognosis on natural conception have not yet been performed.
We believe that such a trial is necessary before such guidelines
are implemented.
Conclusions
We have shown that in vitro fertilisation with single embryo
transfer and in vitro fertilisation in a modified natural cycle
were non-inferior to intrauterine insemination with controlled
ovarian hyperstimulation in terms of the birth of a healthy child,
with comparable multiple pregnancy rates. The absence of a
marked difference in pregnancy outcomes suggests that the
more invasive in vitro fertilisation with single embryo transfer
and in vitro fertilisation in a modified natural cycle may not be
desirable alternatives to intrauterine inseminationwith controlled
ovarian hyperstimulation. In view of these results, there seems
no reason to abandon intrauterine insemination with controlled
ovarian hyperstimulation as a first line treatment of couples
with unexplained or mild male subfertility and an unfavourable
prognosis for natural conception.
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What is already known on this topic
Up to half of subfertile couples are diagnosed as having unexplained or mild male subfertility
If these couples have unfavourable chances of natural conception, intrauterine insemination with controlled ovarian hyperstimulation is
the first line treatment
In vitro fertilisation with single embryo transfer or in vitro fertilisation in a modified natural cycle are alternative treatments that may
prevent multiple pregnancies
What this study adds
In vitro fertilisation with single embryo transfer and in vitro fertilisation in a modified natural cycle were non-inferior to intrauterine
insemination with controlled ovarian hyperstimulation in terms of the birth of a healthy child
Rates of multiple pregnancy were comparable and low in the three group
There seems to be no reason to abandon intrauterine insemination with controlled ovarian hyperstimulation as a first line treatment of
couples with unexplained or mild male subfertility and an unfavourable prognosis for natural conception
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Tables
Table 1| Baseline characteristics of couples. Values are numbers (percentages) unless stated otherwise
IUI-COH (n=207)IVF-MNC (n=194)IVF-SET (n=201)Characteristic
34 (3.67)33 (3.50)33 (3.39)Mean (SD) age of female partner, years
157 (76)141 (73)160 (80)Primary subfertility
2.30 (1.82-3.13)2.14 (1.77-2.81)2.13 (1.73-3.01)Median (IQR) duration of subfertility, years
178 (86)163 (84)182 (91)White
46 (22)35 (18)45 (22)Smoking
23 (21-26)23 (21-25)23 (21-26)Median (IQR) body mass index, kg/m2
59 (30-124)53 (25-126)51 (25-100)Median (IQR) total motile sperm count (×106)
Diagnosis of subfertility:
189 (91)173 (89)183 (91)Unexplained
18 (9)21 (11)18 (9)Male factor
19 (6.38 )21 (6.83)20 (6.56)Mean (SD) Hunault score*
IQR=interquartile range; IUI-COH=intrauterine insemination with controlled ovarian hyperstimulation; IVF-MNC=in vitro fertilisation in modified natural cycle;
IVF-SET=in vitro fertilisation with single embryo transfer.
*Calculated according to formula by Van der Steeg et al 2007.7
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Table 2| Number of couples per intervention







706315Additional treatment within 12 months
IUI-COH=intrauterine insemination with controlled ovarian hyperstimulation; IVF-MNC=in vitro fertilisation in modified natural cycle; IVF-SET=in vitro fertilisation
with single embryo transfer.
*Data in IVF-SET group is number of fresh cycles started; according to protocol, couples received maximum of three fresh cycles of IVF-SET.
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Table 3| Total number of cycles performed within 12 months
IUI-COHIVF-MNCIVF-SETNo of cycles
822632301Total No of fresh cycles
––158Total No of frozen cycles
68385Total additional fresh IVF/ICSI cycles
1770Total additional frozen IVF/ICSI cycles
316145Total additional IUI cycles
ICSI= intracytoplasmic sperm injection; IUI-COH=intrauterine insemination with controlled ovarian hyperstimulation; IVF-MNC=in vitro fertilisation in modified
natural cycle; IVF-SET=in vitro fertilisation with single embryo transfer.
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Table 4| Pregnancy, neonatal, and maternal outcomes. Values are numbers (percentages) unless stated otherwise
Relative risk (95% CI)
IUI-COH (n=207)IVF-MNC (n=194)IVF-SET (n=201) IVF-MNC v IUI-COHIVF-SET v IUI-COH
Pregnancy outcomes
0.91 (0.73 to 1.14)1.10 (0.91 to 1.34)97 (47)83 (43)104 (52)Healthy child
0.91 (0.76 to 1.09)1.05 (0.89 to 1.24)116 (56)99 (51)118 (59)Live birth*
0.91 (0.77 to 1.09)1.05 (0.89 to 1.23)119 (57)102 (53)121 (60)Ongoing pregnancy
0.93 (0.80 to 1.09)1.05 (0.91to 1.21)132 (64)115 (59)135 (67)Clinical pregnancy
0.73 (0.25 to 2.16)0.86 (0.32 to 2.30)8 (7)5 (5)7 (6)Multiple pregnancy†
Neonatal outcomes‡
––000Neonatal mortality
0.88 (0.32 to 2.45)1.11 (0.44 to 2.77)8 (7)6 (6)9 (8)Birth weight <2500 g
0.90 (0.41 to 1.97)0.60 (0.26 to 1.40)13 (11)10 (10)8 (7)Preterm birth <37 weeks
0.94 (0.26 to 3.40)0.20 (0.02 to 1.66)5 (4)4 (4)1 (1)Congenital anomalies
Maternal outcomes
–2.06 (0.19 to 2.54)1 (0)02 (1)Ovarian hyperstimulation
1.07 (0.27 to 4.21)0.26 (0.03 to 2.28)4 (2)4 (2)1 (0)Pregnancy induced
hypertension
0.91 (0.31 to 2.67)0·29 (0.06 to 1.40)7 (3)6 (3)2 (1)Pre-eclampsia
––1 (0)00HELLP syndrome
IUI-COH=intrauterine insemination with controlled ovarian hyperstimulation; IVF-MNC=in vitro fertilisation in modified natural cycle; IVF-SET=in vitro fertilisation
with single embryo transfer.
*One couple in IVF-SET group with ongoing pregnancy could not be contacted for follow-up of pregnancy.
†Percentage is ratio of total ongoing pregnancies. Three monochorial twins: two in IVF-MNC group and one in IUI-COH group.
‡Percentage is ratio of total live births.
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Figures
Fig 1 Flow chart of study. IUI-COH=intrauterine insemination with controlled ovarian hyperstimulation; IVF-MNC=in vitro
fertilisation in modified natural cycle; IVF-SET=in vitro fertilisation with single embryo transfer
Fig 2 Time to pregnancy resulting in healthy child. IUI-COH=intrauterine insemination with controlled ovarian hyperstimulation;
IVF-MNC=in vitro fertilisation in modified natural cycle; IVF-SET=in vitro fertilisation with single embryo transfer
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Fig 3Cumulative chances of ongoing pregnancy. IUI-COH=intrauterine insemination with controlled ovarian hyperstimulation;
IVF-MNC=in vitro fertilisation in modified natural cycle; IVF-SET=in vitro fertilisation with single embryo transfer
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